In vitro selection and identification of HIV strain which is resistance to two new HIV-1 nonnucleoside reverse transcriptase inhibitors

Yaoxue Xuebao

Volumn 45, Issue 2, 2010, Pages 241-246

  Liu, Si Yang ^a   Zhuang, Dao Min ^a   Dong, Ru Hua ^a   Bai, Li ^a   Li, Jing Yun ^a  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

Human immunodeficiency virus type 1; Mutation; Nonnucleoside reverse transcriptase inhibitor; Resistant variant

Indexed keywords

JB 25; JB 26; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DRUG POTENCY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; NONHUMAN; VIRUS RESISTANCE; VIRUS STRAIN;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTI-HIV AGENTS; CELL LINE; CODON; DRUG RESISTANCE, VIRAL; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 77950928412     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Buonaguro L, Tornesello ML, Buonaguro FM. Human immunodeficiency virus type 1 subtype distribution in the worldwide epidemic: pathogenetic and therapeutic implications [J]. J Virol, 2007, 81: 10209-10219. (Pubitemid 47463296)
2. Vergne L, Peeters M, Mpoudi-Ngole E, et al. Genetic diversity of protease and reverse transcriptase sequences in non-subtype-B human immunodeficiency virus type 1 strains: evidence of many minor drug resistance mutations in treatment-naive patients [J]. J Clin Microbiol, 2000, 38: 3919-3925. (Pubitemid 32233182)
3. Jones GS, Yu F, Zeynalzadegan A, et al. Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase [J]. Antimicrob Agents Chemother, 2009, 53: 1194-1203.
4. Mellors JW, Dutschman GE, Im G-J, et al. In vitro selection and molecular characterization of human immunodeficiency virus-1 resistant to non-nucleoside inhibitors of reverse transcriptase [J]. Mol Pharmacol, 1992, 41: 446-451.
5. Vingerhoets J, Azijn H, Fransen E, et al. TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments [J]. J Virol, 2005, 79: 12773-12782. (Pubitemid 41433197)
6. Jiang B, Xu M. Highly enantioselective construction of fused pyrrolidine systems that contain a quaternary stereocenter: concise formal synthesis of (+)-conessine [J]. Angew Chem (Int Ed Engl), 2004, 43: 2543-2546.
7. Pauwels R, Balzarini J, Baba M, et al. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds [J]. J Virol Methods, 1988, 20: 309-321.
8. Hazen RJ, Harvey RJ, St. Clair MH, et al. Anti-human immunodeficiency virus type 1 activity of the nonnucleoside reverse transcriptase inhibitor GW678248 in combination with other antiretrovirals against clinical isolate viruses and in vitro selection for resistance [J]. Antimicrob Agents Chemother, 2005, 49: 4465-4473.
9. Sham HL, Kempf DJ, Molla A, et al. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease [J]. Antimicrob Agents Chemother, 1998, 42: 3218-3224. (Pubitemid 28553744)
10. Li JY, Li HP, Li L, et al. Prevalence and evolution of drug resistance HIV-1 variants in Henan, China [J]. Cell Res, 2005, 15: 843-849.
11. Johnson VA, Brun-Vézinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: December 2008 [J]. Top HIV Med, 2008, 16: 138-145.
12. Basavapathruni A, Anderson KS. Reverse transcription of the HIV-1 pandemic [J]. FASEB J, 2007, 21: 3795-3808.
13. Shafer RW, Schapiro JM. HIV-1 drug resistance mutations: an updated framework for the second decade of HAART [J]. AIDS Rev, 2008, 10: 67-84.
14. Iglesias-Ussel MD, Casado C, Yuste E, et al. In vitro analysis of human immunodeficiency virus type 1 resistance to nevirapine and fitness determination of resistant variants [J]. J Gen Virol, 2002, 83: 93-101.
15. Corbett JW, Ko SS, Rodgers JD, et al. Expanded-spectrum nonnucleoside reverse transcriptase inhibitors inhibit clinically relevant mutant variants of human immunodeficiency virus type 1 [J]. Antimicrob Agents Chemother, 1999, 43: 2893-2897.
16. Collins JA, Thompson MG Paintsil E, et al. Competitive fitness of nevirapine-resistant human immunodeficiency virus type 1 mutants [J]. J Virol, 2004, 78: 603-611. (Pubitemid 38067582)
17. Ren J, Stammers DK. Structural basis for drug resistance mechanisms for non-nucleoside inhibitors of HIV reverse transcriptase [J]. Virus Res, 2008, 134: 157-170.